89bio's phase 2b enliven trial of pegozafermin in nonalcoholic steatohepatitis (nash) achieved high statistical significance on both primary histology endpoints with weekly (qw) and every-two-week (q2w) dosing at 24 weeks

- 44mg q2w dose had a placebo-adjusted effect size of 20% on at least one-stage fibrosis improvement without worsening of nash (p=0.008) and 24% on nash resolution without worsening of fibrosis (p=0.0005) -

ETNB Ratings Summary

ETNB Quant Ranking